Vanguard Investments Australia
MLTX icon

Vanguard Investments Australia’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vanguard Investments Australia’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Hold
8,935
– – ﹤0.01% 2167
2026
Q1 		$167K Buy
+8,935
New +$148K ﹤0.01% 2124

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Investments Australia's MLTX Position: Q2 2026 in Review

Vanguard Investments Australia held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 8,935 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Vanguard Investments Australia first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Vanguard Investments Australia held 8,935 shares of MoonLake Immunotherapeutics worth $174K as of Q2 2026.
  • Vanguard Investments Australia left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2167 holding.
  • Vanguard Investments Australia first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.